Tuberculosis
📧 Sign up to get email alerts when something new happens for Tuberculosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2020-07-17Clinical Trial Update: The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin [Phase 1, Phase 2]
Phase 1/2 trial updating pharmacokinetics and safety of IDV/r with NRTIs in HIV/TB co-infected patients on rifampicin.
-
CLINICAL_TRIALS trial_result · 2020-07-17Clinical Trial Update: Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy [Phase 2]
Phase 2 trial assessing pharmacokinetics and safety of two dose regimens of lopinavir/ritonavir in HIV/TB co-infected patients on rifampicin…
-
FDA approval · 2020-07-01FDA Approved: RIFAMPIN — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Rifampin filed by Mylan Institutional LLC (ANDA065421). This action represents a supplementa…
-
CLINICAL_TRIALS trial_result · 2020-06-30Clinical Trial Update: Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention [Phase 3]
Phase 3 trial update on weekly rifapentine and isoniazid for prevention of tuberculosis in silicosis and tuberculosis conditions.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac [Phase 2]
Phase II trial assessing safety and immunogenicity of the recombinant subunit tuberculosis vaccine GamTBvac has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-06-09FDA Approved: PRIFTIN — Supplemental Application (sanofi-aventis U.S. LLC)
The FDA approved a supplemental application for Priftin (rifapentine) filed by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2020-06-05FDA Approved: PRIFTIN — Supplemental Application (sanofi-aventis U.S. LLC)
The FDA approved a supplemental application for PRIFTIN (rifapentine) from Sanofi-US LLC, signaling regulatory approval related to a labelin…
-
FDA approval · 2020-05-27FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) submitted by Janssen Products, LP, updating the drug's approv…
-
CLINICAL_TRIALS trial_result · 2020-05-06Clinical Trial Update: Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pharmacokinetics, tolerability, and safety of rifapentine and isoniazid in pregnant and postpartum women…
-
CLINICAL_TRIALS trial_result · 2020-04-13Clinical Trial Update: Phase 1 Study of PBTZ169 [Phase 1]
Phase 1 study of PBTZ169 for tuberculosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-24Clinical Trial Update: Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi [NA]
Completed clinical trial evaluating training lay healthcare workers to improve tuberculosis care and outcomes in Malawi; results posted in 2…
-
CLINICAL_TRIALS trial_result · 2020-03-24Clinical Trial Update: Taima TB: 3HP Study [Phase 4]
Phase 4 clinical trial update for Taima TB: 3HP study investigating regimen for tuberculosis has completed.
-
CLINICAL_TRIALS trial_result · 2020-03-18Clinical Trial Update: Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation [Phase 4]
Phase 4 clinical trial updating rapid PCR-based detection of rifampin and isoniazid resistance in tuberculosis before treatment initiation.
-
CLINICAL_TRIALS trial_result · 2020-03-09Clinical Trial Update: Phase 2a Study of PBTZ169 [Phase 2]
Phase 2a study of PBTZ169 for tuberculosis was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Innovative Approach in Tuberculosis Care in Armenia [NA]
Clinical trial update for an innovative tuberculosis care approach completed in Armenia with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-13Clinical Trial Update: Optimization of the TB Treatment Regimen Cascade [Phase 3]
Phase 3 clinical trial update on optimizing the tuberculosis treatment regimen cascade; study completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-12Clinical Trial Update: Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly [Phase 2]
Phase 2 trial comparing pharmacokinetics and safety of rifabutin 150 mg daily versus 300 mg thrice weekly in HIV and tuberculosis.
-
CLINICAL_TRIALS trial_result · 2020-01-29Clinical Trial Update: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis [Phase 2]
Phase 2 trial evaluating safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, for drug-resista…
-
FDA approval · 2020-01-06FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) submitted by Janssen Products, LP.
-
CLINICAL_TRIALS trial_result · 2019-12-19Clinical Trial Update: A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456) [Phase 1, Phase 2]
Phase I/IIa trial update for AERAS-456 in HIV-negative adults with and without latent tuberculosis infection has completed with results post…
-
CLINICAL_TRIALS trial_result · 2019-12-17Clinical Trial Update: Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis [Phase 2]
Phase 2 trial assessing adjunctive ibuprofen for efficacy and safety in XDR-TB tuberculosis; study completed.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults [Phase 2]
Phase 2 trial update on GSK's TB vaccine in adults; study completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB [Phase 1]
Phase I study assessing safety and immunogenicity of the TB vaccine AERAS-456 in HIV-negative adults treated for drug-susceptible pulmonary …
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents [Phase 1]
Phase 1 safety and immunogenicity trial updating results for revaccination with BCG, H4:IC31, and H56:IC31 in healthy adolescents for tuberc…
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals [Phase 3]
Phase 3 trial evaluating 3HP regimens vs 6H in HIV-positive individuals with tuberculosis has completed.